Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics announced new formulary agreements that increase access to ZELSUVMI (berdazimer) topical gel, a novel treatment for molluscum contagiosum, to a total of 127 million commercially covered lives plus strong Medicaid coverage. This includes a major Pharmacy Benefit Manager covering 24 million lives without prior authorization and a…